Zacks Investment Research cut shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) from a buy rating to a hold rating in a research note released on Wednesday, reports.

According to Zacks, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom. “

Several other brokerages have also recently weighed in on SMMT. TheStreet cut SUMMIT THERAPEU/S from a c- rating to a d- rating in a research report on Friday, October 11th. ValuEngine upgraded SUMMIT THERAPEU/S from a sell rating to a hold rating in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $1.88.

Shares of NASDAQ SMMT traded up $0.02 during mid-day trading on Wednesday, hitting $1.61. The company had a trading volume of 100 shares, compared to its average volume of 59,241. The company has a market capitalization of $51.20 million, a price-to-earnings ratio of 1.92 and a beta of 1.25. SUMMIT THERAPEU/S has a 1 year low of $1.10 and a 1 year high of $2.46. The company has a current ratio of 3.47, a quick ratio of 3.93 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $1.49 and its 200-day moving average price is $1.53.

A hedge fund recently raised its stake in SUMMIT THERAPEU/S stock. Morgan Stanley boosted its holdings in shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) by 7.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 244,201 shares of the company’s stock after buying an additional 16,245 shares during the period. Morgan Stanley owned approximately 1.76% of SUMMIT THERAPEU/S worth $309,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.30% of the company’s stock.


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Read More: What is the Rule of 72?

Get a free copy of the Zacks research report on SUMMIT THERAPEU/S (SMMT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with's FREE daily email newsletter.